JPH07277986A - Antibacterial agent ingredient containing bile acid salt as main ingredient and used against methicillin-resistant staphylococcus aureus - Google Patents
Antibacterial agent ingredient containing bile acid salt as main ingredient and used against methicillin-resistant staphylococcus aureusInfo
- Publication number
- JPH07277986A JPH07277986A JP10425894A JP10425894A JPH07277986A JP H07277986 A JPH07277986 A JP H07277986A JP 10425894 A JP10425894 A JP 10425894A JP 10425894 A JP10425894 A JP 10425894A JP H07277986 A JPH07277986 A JP H07277986A
- Authority
- JP
- Japan
- Prior art keywords
- staphylococcus aureus
- resistant staphylococcus
- methicillin
- antibacterial agent
- ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【０００１】[0001]
【発明の目的】本発明は、メチシリン耐性黄色ブドウ球
菌による薬剤耐性が知られていない、胆汁酸塩類を主成
分とする、同菌に対する抗菌剤である。OBJECT OF THE INVENTION The present invention is an antibacterial agent containing bile salts as a main component, which has no known drug resistance due to methicillin-resistant Staphylococcus aureus.
【０００２】[0002]
【産業上の利用分野】メチシリン耐性黄色ブドウ球菌を
対象とした抗菌剤成分である。[Industrial application] This is an antibacterial agent for methicillin-resistant Staphylococcus aureus.
【０００３】[0003]
【従来の技術】病院および老人施設等におけるメチシリ
ン耐性黄色ブドウ球菌による器物等の汚染に対しては、
塩化ベンザルコニウム、塩化ベンゼトニウムなどの第４
級アンモニウム系消毒剤ならびにクロルヘキシジン等の
ビグアナイド系消毒剤、またポピドンヨードなどのヨウ
素系消毒剤等が主に使用されている（「第１２版・日本
薬局方」）。2. Description of the Related Art For contamination of articles and the like by methicillin-resistant Staphylococcus aureus in hospitals and facilities for the elderly
Fourth such as benzalkonium chloride and benzethonium chloride
Primarily ammonium-based disinfectants, biguanide-based disinfectants such as chlorhexidine, and iodine-based disinfectants such as povidone-iodine are mainly used ("Twelfth Edition, Japanese Pharmacopoeia").
【０００４】[0004]
【発明が解決しようとする課題】メチシリン耐性黄色ブ
ドウ球菌による居住環境や器物汚染に対しては、第４級
アンモニウム系消毒剤、ビグアナイド系消毒剤ならびに
ヨウ素系消毒剤など、従来より使用されている薬剤によ
る対応がなされている。しかし、１９８４年にオースト
ラリアで初めて第４級アンモニウム系消毒剤に対して耐
性を獲得したメチシリン耐性黄色ブドウ球菌の存在が確
認され、その後、この消毒剤耐性のメチシリン耐性黄色
ブドウ球菌は消毒剤に対する耐性遺伝子（ｅｒｂ）を持
つとともに、同遺伝子が混合培養系で他のメチシリン耐
性黄色ブドウ球菌に取り込まれることが判明し、またそ
の４０％に消毒剤耐性が認められた。さらに近年には、
同遺伝子重複（ｅｒｂ−ｅｒｂ）による高度耐性菌の出
現も明らかになっている（河野恵、日本細菌学会関東支
部ニュース、第２０号、１９９３年）。このように、メ
チシリン耐性黄色ブドウ球菌に対して従来の消毒剤に頼
っていることは、これら薬剤への耐性を獲得した同菌の
出現を招く可能性がある。Problems to be Solved by the Invention Quaternary ammonium-based disinfectants, biguanide-based disinfectants, iodine-based disinfectants and the like have been conventionally used for the contamination of living environments and articles by methicillin-resistant Staphylococcus aureus. Correspondence is made by drugs. However, the existence of methicillin-resistant Staphylococcus aureus that acquired resistance to quaternary ammonium-based disinfectants for the first time in Australia in 1984 was confirmed. In addition to having the gene ( erb ), it was found that the same gene was taken up by other methicillin-resistant Staphylococcus aureus in the mixed culture system, and 40% of the gene was confirmed to have antiseptic resistance. More recently,
The emergence of highly resistant bacteria due to the same gene duplication ( erb - erb ) has also been revealed (Megumi Kono, Kanto Branch News, No. 20, 1993, Japanese Society of Bacteriology). Thus, reliance on conventional antiseptics against methicillin-resistant Staphylococcus aureus may lead to the emergence of the same bacteria that have acquired resistance to these agents.
【０００５】[0005]
【課題を解決するための手段】発明者らは、従来の消毒
剤の概念から大きく発想を転換し、デオキシコール酸な
どの胆汁酸塩類によるメチシリン耐性黄色ブドウ球菌の
細胞膜を破壊する研究を重ねた結果、本発明を完成させ
るにいたった。尚、発明者らはすでに本発明における主
成分である胆汁酸塩を主成分とした、ヒトの皮膚に常在
するスタヒロコッカス属菌の制御を目的とする発明およ
び報告を行っているが（特開平３−５８９１８号公報お
よび日本細菌学雑誌、第４５巻、第４号、ｐ．７９７−
７９９、１９９０年）、これらはいずれも表皮ブドウ球
菌を対象としたものであった。[Means for Solving the Problems] The inventors of the present invention have changed their ideas from the conventional concept of disinfectants and have conducted repeated studies to destroy the cell membrane of methicillin-resistant Staphylococcus aureus by bile salts such as deoxycholic acid. As a result, the present invention has been completed. In addition, the inventors have already made an invention and a report aiming at the control of Staphylococcus spp., Which is a main component of the present invention, which is a main component of the present invention, and which is resident in human skin ( JP-A-3-58918 and Japanese Journal of Bacteriology, Vol. 45, No. 4, p. 797-
799, 1990), all of which were targeted to S. epidermidis.
【０００６】[0006]
【０００７】検体として、デオキシコール酸ナトリウム
塩を精製水に１重量％溶解した水溶液を５段階に２倍段
階稀釈した。As a sample, an aqueous solution in which 1% by weight of deoxycholate sodium salt was dissolved in purified water was diluted twice in five steps.
【０００８】供試菌はヒトより分離した黄色ブドウ球菌
のうち、メチシリン耐性菌株を用い、ＳＣＤブロスにて
２継代培養したものを用いた。As the test bacteria, among Staphylococcus aureus isolated from human, a methicillin-resistant strain was used, which was subcultured for 2 passages in SCD broth.
【０００９】抗菌力試験は、モノディスク法によった。The antibacterial activity test was based on the monodisk method.
【００１０】抗菌効果の判定基準は、モノディスク法に
準じて阻止円帯の直径が９ミリ以上を抗菌効果ありと判
定した。The antibacterial effect was determined according to the Monodisc method by determining that the diameter of the inhibition zone was 9 mm or more as having the antibacterial effect.
【００１１】[0011]
【発明の効果】各検体の結果は以下の表１に示した通り
である。 以上より、本発明はメチシリン耐性黄色ブドウ球菌に対
して抗菌作用を有することが示された。The results of each sample are shown in Table 1 below. From the above, it was shown that the present invention has an antibacterial action against methicillin-resistant Staphylococcus aureus.
Claims (3)
その塩の各単体および、または組み合わせたものを主成
分とするメチシリン耐性黄色ブドウ球菌用抗菌剤成分1. An antibacterial ingredient for methicillin-resistant Staphylococcus aureus, which comprises deoxycholic acid as a bile salt, or a salt thereof alone or in combination.
％以上のエタノール溶液、または濃度３０重量％以上の
イソプロピルアルコールに添加した「請求項１」に記載
のメチシリン耐性黄色ブドウ球菌用抗菌剤成分2. An antibacterial agent component for methicillin-resistant Staphylococcus aureus according to claim 1, which is added to water and / or an ethanol solution having a concentration of 40% by weight or more, or isopropyl alcohol having a concentration of 30% by weight or more as a solvent.
その塩の各単体および、または組み合わせたものを０．
０６重量％以上を含有するところの、「請求項１」およ
び「請求項２」に記載のメチシリン耐性黄色ブドウ球菌
用抗菌剤成分3. Deoxycholic acid or a salt thereof as a bile salt is used alone or in combination.
The antibacterial agent component for methicillin-resistant Staphylococcus aureus according to claim 1, which contains not less than 06% by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10425894A JPH07277986A (en) | 1994-04-08 | 1994-04-08 | Antibacterial agent ingredient containing bile acid salt as main ingredient and used against methicillin-resistant staphylococcus aureus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10425894A JPH07277986A (en) | 1994-04-08 | 1994-04-08 | Antibacterial agent ingredient containing bile acid salt as main ingredient and used against methicillin-resistant staphylococcus aureus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH07277986A true JPH07277986A (en) | 1995-10-24 |
Family
ID=14375911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10425894A Pending JPH07277986A (en) | 1994-04-08 | 1994-04-08 | Antibacterial agent ingredient containing bile acid salt as main ingredient and used against methicillin-resistant staphylococcus aureus |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH07277986A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998031372A1 (en) * | 1997-01-16 | 1998-07-23 | Dr. Kief Lizenz Verwertungs Gesellschaft Mbh | Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures |
| EP1933856A2 (en) * | 2005-08-29 | 2008-06-25 | Sepsicure L.L.C. | Method for treatment or prevention of conditions caused by gram-positive bacteria |
-
1994
- 1994-04-08 JP JP10425894A patent/JPH07277986A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998031372A1 (en) * | 1997-01-16 | 1998-07-23 | Dr. Kief Lizenz Verwertungs Gesellschaft Mbh | Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures |
| US6407085B1 (en) | 1997-01-16 | 2002-06-18 | Horst Kief | Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures |
| EP1933856A2 (en) * | 2005-08-29 | 2008-06-25 | Sepsicure L.L.C. | Method for treatment or prevention of conditions caused by gram-positive bacteria |
| EP1933856A4 (en) * | 2005-08-29 | 2008-11-19 | Sepsicure L L C | Method for treatment or prevention of conditions caused by gram-positive bacteria |
| JP2009506120A (en) * | 2005-08-29 | 2009-02-12 | セプシキュア、リミテッド、ライアビリティ、カンパニー | Methods for treating or preventing conditions caused by Gram-positive bacteria |
| AU2006284990B2 (en) * | 2005-08-29 | 2011-01-06 | Sepsicure L.L.C. | Method for treatment or prevention of conditions caused by gram-positive bacteria |
| KR101413361B1 (en) * | 2005-08-29 | 2014-06-27 | 셉시큐어,엘.엘.씨. | Method for treatment or prevention of conditions caused by gram-positive bacteria |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6479532B1 (en) | Antifungal compositions | |
| Osmanov et al. | The antiseptic Miramistin: a review of its comparative in vitro and clinical activity | |
| JP2002524475A (en) | Topical transdermal antimicrobial composition | |
| Modak et al. | Combined topical use of silver sulfadiazine and antibiotics as a possible solution to bacterial resistance in burn wounds | |
| PT806941E (en) | LIPOSOMIC ANTI-BACTERIAL COMPOSITIONS OF LOW RIGIDITY | |
| US20040072898A1 (en) | Inhibition of gram positive bacteria | |
| EP2987408A1 (en) | Iodophor composition with improved stability in the presence of organic material | |
| US11331289B2 (en) | Antimicrobial composition | |
| KR100457851B1 (en) | A pharmaceutical composition for the treatment of skin infections which are caused by antibiotic-resistant bacteria comprising 1-hydroxy-2-pyridones | |
| WO2019083397A1 (en) | Solubilization of chlorhexidine base, anitseptic composition and disinfectant composition | |
| Zeelie | Effects of copper and zinc ions on the germicidal properties of two popular pharmaceutical antiseptic agents cetylpyridinium chloride and povidone-iodine | |
| DE102007030103A1 (en) | Use of a synergistic composition as a therapeutic or cosmetic agent | |
| Lewin et al. | The bactericidal activity of DR-3355, an optically active isomer of ofloxacin | |
| JPH07277986A (en) | Antibacterial agent ingredient containing bile acid salt as main ingredient and used against methicillin-resistant staphylococcus aureus | |
| JP3499882B2 (en) | Disinfectant for viscous rubbing | |
| EP0090577B1 (en) | Insoluble polymeric contact preservatives | |
| EP0154622A1 (en) | Antimicrobial compositions containing 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid or metal salts thereof and silver sulfadiazine | |
| KR20040062561A (en) | Anti-microbial composition comprising a metal ion cheating agent | |
| US7973080B2 (en) | Method for inhibiting the growth of antibiotic resistant of bacteria by using pentane-1,5-diol | |
| JP2958344B2 (en) | Antibacterial agent | |
| DE3686459T2 (en) | Non-irritating teat dip composition. | |
| Lewin et al. | Conditions required for the bactericidal activity of fleroxacin and pefloxacin against Escherichia coli KL 16 | |
| JP3054758B2 (en) | Trauma composition | |
| EP0076430B1 (en) | Compositions having antimicrobial activity | |
| Bauernfeind et al. | Bactericidal kinetics of various dosages of fleroxacin simulated in bacterial cultures |